24 research outputs found
Gene Therapy Medicinal Products: Non-clinical Safety Studies
Currently, gene therapy medicinal products (GTMPs) are actively developed in many countries, including the Russian Federation. However, the use of GTMPs raises class-specific safety concerns.The aim of the study was to determine the main requirements for non-clinical safety testing of GTMPs, to identify risks associated with these medicinal products, to establish criteria for expert assessments, and to find optimisation opportunities for GTMP non-clinical safety programmes, using Russian and international experience in the assessment of submissions and the registration of medicinal products of this class.The Russian Federation, the Eurasian Economic Union, the European Union, and the United States have created regulatory frameworks governing the lifecycle of GTMPs and continue improving these frameworks. The properties of GTMPs may create unique safety issues, such as insertional mutagenesis, unregulated transgene expression, long-term persistence and off-target spread, vertical germline transmission, and environmental risks. To account for these issues, a comprehensive non-clinical safety programme for GTMPs may require additional special studies along with the standard ones. This review focuses on the main approaches to designing non-cellular GTMP safety studies and evaluating the obtained results. The authors identified improvement opportunities for and problematic aspects of study design, as well as conditions for and limitations of non-clinical data extrapolation and clinical safety profile prediction. The continuous improvement and updating of the regulatory frameworks governing non-clinical studies of GTMPs mean that developers of non-clinical safety programmes for GTMPs should use all their experience, as well as relevant national and international guidelines and recommendations
Study of the relationship between professional self-determination and communication skills in adolescents and young men
The relevance of the research is based on the need to study the factors affecting the professional self-determination of adolescents and young men, including their communicative skills and the characteristics of peer groups, to which young people belong and are affected by. The aim of the research was to study the interrelationship between the indicators of professional self-determination and the communication skill levels in adolescents and young men. Hypothesis of the research: 1. In adolescent boys, unlike teenage girls, the choice of profession is more uncertain. 2. Schoolchildren and students have significant links between the indicators of professional self-determination and their communication skill levels. 3. There is a link between the indicators of professional self-determination and belonging to the group. In the empirical study, the following methods were used: "The Personal Professional Path" questionnaire edited by N. Pryazhnikov, the "Differential-diagnostic Questionnaire" by E. Klimova, the method "Communication and Organizational Propensity" (COS-2) by V. Sinyavsky and B. Fedorishin, the "Sociometry" Method by J. Moreno. The sample of 159 people consisted of students of the 7th and 10th grades, students of the Ural Federal University. The external and internal motives of choosing a profession by adolescents and young men were examined and empirically studied, secondly, the relationship between the choice of profession and professional inclinations, and thirdly, the interrelation of communicative and professional inclinations. The first hypothesis was confirmed by the positive correlation between communicative inclinations and professional intentions in the category "man-man" in respondents. The second hypothesis was partially confirmed: in two classes and in one student group, the differences between the mini-groups were determined by the criterion of professional inclinations, i.e. professional inclinations can be a factor uniting the students in mini-groups, but the final professional choice within the groups is different, therefore, determined by other factors.ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ²ΡΠ·Π°Π½Π° Ρ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡΡ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ ΡΠ°ΠΊΡΠΎΡΠΎΠ², Π²Π»ΠΈΡΡΡΠΈΡ
Π½Π° ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ΅ ΡΠ°ΠΌΠΎΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠΎΠ΄ΡΠΎΡΡΠΊΠΎΠ² ΠΈ ΡΠ½ΠΎΡΠ΅ΠΉ, ΠΊ ΡΠΈΡΠ»Ρ ΠΊΠΎΡΠΎΡΡΡ
ΠΎΡΠ½ΠΎΡΡΡΡΡ ΠΈΡ
ΠΊΠΎΠΌΠΌΡΠ½ΠΈΠΊΠ°ΡΠΈΠ²Π½ΠΎΠ΅ ΠΊΠ°ΡΠ΅ΡΡΠ²Π°, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ Π³ΡΡΠΏΠΏ ΡΠ²Π΅ΡΡΡΠ½ΠΈΠΊΠΎΠ², ΠΊ ΠΊΠΎΡΠΎΡΡΠΌ ΠΏΡΠΈΠ½Π°Π΄Π»Π΅ΠΆΠ°Ρ ΠΌΠΎΠ»ΠΎΠ΄ΡΠ΅ Π»ΡΠ΄ΠΈ ΠΈ ΠΈΡΠΏΡΡΡΠ²Π°ΡΡ Π½Π° ΡΠ΅Π±Π΅ ΠΈΡ
Π²Π»ΠΈΡΠ½ΠΈΠ΅. Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π·Π°ΠΊΠ»ΡΡΠ°Π»Π°ΡΡ Π² ΠΈΠ·ΡΡΠ΅Π½ΠΈΠΈ Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·ΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠ°ΠΌΠΎΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΠΈ ΡΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½Π½ΠΎΡΡΠΈ ΠΊΠΎΠΌΠΌΡΠ½ΠΈΠΊΠ°ΡΠΈΠ²Π½ΡΡ
ΠΊΠ°ΡΠ΅ΡΡΠ² Π»ΠΈΡΠ½ΠΎΡΡΠΈ Π² ΠΏΠΎΠ΄ΡΠΎΡΡΠΊΠΎΠ²ΠΎΠΌ ΠΈ ΡΠ½ΠΎΡΠ΅ΡΠΊΠΎΠΌ Π²ΠΎΠ·ΡΠ°ΡΡΠ΅. ΠΠΈΠΏΠΎΡΠ΅Π·Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: 1. Π£ ΠΏΠΎΠ΄ΡΠΎΡΡΠΊΠΎΠ²-ΡΠ½ΠΎΡΠ΅ΠΉ, Π² ΠΎΡΠ»ΠΈΡΠΈΠ΅ ΠΎΡ ΠΏΠΎΠ΄ΡΠΎΡΡΠΊΠΎΠ²-Π΄Π΅Π²ΡΡΠ΅ΠΊ, Π²ΡΠ±ΠΎΡ ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΈ ΠΎΡΠ»ΠΈΡΠ°Π΅ΡΡΡ Π±ΠΎΠ»ΡΡΠ΅ΠΉ Π½Π΅ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π½ΠΎΡΡΡΡ. 2. Π£ ΡΠΊΠΎΠ»ΡΠ½ΠΈΠΊΠΎΠ² ΠΈ ΡΡΡΠ΄Π΅Π½ΡΠΎΠ² ΠΈΠΌΠ΅ΡΡΡΡ Π·Π½Π°ΡΠΈΠΌΡΠ΅ ΡΠ²ΡΠ·ΠΈ ΠΌΠ΅ΠΆΠ΄Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠ°ΠΌΠΎΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΠΈ ΡΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½Π½ΠΎΡΡΡΡ ΠΊΠΎΠΌΠΌΡΠ½ΠΈΠΊΠ°ΡΠΈΠ²Π½ΡΡ
ΠΊΠ°ΡΠ΅ΡΡΠ². 3. Π‘ΡΡΠ΅ΡΡΠ²ΡΠ΅Ρ ΡΠ²ΡΠ·Ρ ΠΌΠ΅ΠΆΠ΄Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠ°ΠΌΠΎΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΠΈ ΠΏΡΠΈΠ½Π°Π΄Π»Π΅ΠΆΠ½ΠΎΡΡΡΡ ΠΊ Π³ΡΡΠΏΠΏΠ΅. Π ΡΠΌΠΏΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈΡΡ ΡΠ»Π΅Π΄ΡΡΡΠΈΠ΅ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠΈ: Π°Π½ΠΊΠ΅ΡΠ° Β«ΠΠΈΡΠ½ΡΠΉ ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠΉ ΠΏΡΡΡΒ» ΠΏΠΎΠ΄ ΡΠ΅Π΄Π°ΠΊΡΠΈΠ΅ΠΉ Π. Π‘. ΠΡΡΠΆΠ½ΠΈΠΊΠΎΠ²Π°, Β«ΠΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎ-Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΎΠΏΡΠΎΡΠ½ΠΈΠΊΒ» Π. Π. ΠΠ»ΠΈΠΌΠΎΠ²Π°, ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠ° Β«ΠΠΎΠΌΠΌΡΠ½ΠΈΠΊΠ°ΡΠΈΠ²Π½ΡΠ΅ ΠΈ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΎΠ½Π½ΡΠ΅ ΡΠΊΠ»ΠΎΠ½Π½ΠΎΡΡΠΈΒ» (ΠΠΠ‘ β 2) Π. Π. Π‘ΠΈΠ½ΡΠ²ΡΠΊΠΈΠΉ, Π. Π. Π€Π΅Π΄ΠΎΡΠΈΡΠΈΠ½Π°, ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠ° Β«Π‘ΠΎΡΠΈΠΎΠΌΠ΅ΡΡΠΈΡΒ» ΠΠΆ. ΠΠΎΡΠ΅Π½ΠΎ. ΠΡΠ±ΠΎΡΠΊΠ° Π² ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅ 159 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ ΡΠΎΡΡΠΎΡΠ»Π° ΠΈΠ· ΡΡΠ°ΡΠΈΡ
ΡΡ 7-Ρ
ΠΈ 10-Ρ
ΠΊΠ»Π°ΡΡΠΎΠ², ΡΡΡΠ΄Π΅Π½ΡΠΎΠ² Π£ΡΠ°Π»ΡΡΠΊΠΎΠ³ΠΎ ΡΠ΅Π΄Π΅ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠ½ΠΈΠ²Π΅ΡΡΠΈΡΠ΅ΡΠ°. ΠΡΠ»ΠΈ ΡΠ°ΡΡΠΌΠΎΡΡΠ΅Π½Ρ ΠΈ ΡΠΌΠΏΠΈΡΠΈΡΠ΅ΡΠΊΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ Π²Π½Π΅ΡΠ½ΠΈΠ΅ ΠΈ Π²Π½ΡΡΡΠ΅Π½Π½ΠΈΠ΅ ΠΌΠΎΡΠΈΠ²Ρ Π²ΡΠ±ΠΎΡΠ° ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΈ Ρ ΠΏΠΎΠ΄ΡΠΎΡΡΠΊΠΎΠ² ΠΈ ΡΠ½ΠΎΡΠ΅ΠΉ, Π²ΠΎ-Π²ΡΠΎΡΡΡ
, Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·Ρ Π²ΡΠ±ΠΎΡΠ° ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΈ ΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΡΠΊΠ»ΠΎΠ½Π½ΠΎΡΡΠ΅ΠΉ, Π²-ΡΡΠ΅ΡΡΠΈΡ
, Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·Ρ ΠΊΠΎΠΌΠΌΡΠ½ΠΈΠΊΠ°ΡΠΈΠ²Π½ΡΡ
ΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΡΠΊΠ»ΠΎΠ½Π½ΠΎΡΡΠ΅ΠΉ. ΠΠ΅ΡΠ²Π°Ρ Π³ΠΈΠΏΠΎΡΠ΅Π·Π° ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π΅Π½Π° Π½Π°Π»ΠΈΡΠΈΠ΅ΠΌ Ρ ΡΠ΅ΡΠΏΠΎΠ½Π΄Π΅Π½ΡΠΎΠ² ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΈ ΠΌΠ΅ΠΆΠ΄Ρ ΠΊΠΎΠΌΠΌΡΠ½ΠΈΠΊΠ°ΡΠΈΠ²Π½ΡΠΌΠΈ ΡΠΊΠ»ΠΎΠ½Π½ΠΎΡΡΡΠΌΠΈ ΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠΌΠΈ Π½Π°ΠΌΠ΅ΡΠ΅Π½ΠΈΡΠΌΠΈ Π² ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠΈ Β«ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ β ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΒ». ΠΡΠΎΡΠ°Ρ Π³ΠΈΠΏΠΎΡΠ΅Π·Π° ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠ΄ΠΈΠ»Π°ΡΡ ΡΠ°ΡΡΠΈΡΠ½ΠΎ: Π² Π΄Π²ΡΡ
ΠΊΠ»Π°ΡΡΠ°Ρ
ΠΈ ΠΎΠ΄Π½ΠΎΠΉ ΡΡΡΠ΄Π΅Π½ΡΠ΅ΡΠΊΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅ Π²ΡΡΠ²Π»Π΅Π½Ρ ΡΠ°Π·Π»ΠΈΡΠΈΡ ΠΌΠ΅ΠΆΠ΄Ρ ΠΌΠΈΠ½ΠΈ-Π³ΡΡΠΏΠΏΠ°ΠΌΠΈ ΠΏΠΎ ΠΊΡΠΈΡΠ΅ΡΠΈΡ ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΡΠΊΠ»ΠΎΠ½Π½ΠΎΡΡΠ΅ΠΉ, Ρ.Π΅. ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠ΅ ΡΠΊΠ»ΠΎΠ½Π½ΠΎΡΡΠΈ ΠΌΠΎΠ³ΡΡ Π±ΡΡΡ ΡΠ°ΠΊΡΠΎΡΠΎΠΌ, ΠΎΠ±ΡΠ΅Π΄ΠΈΠ½ΡΡΡΠΈΠΌ Π² ΠΌΠΈΠ½ΠΈ-Π³ΡΡΠΏΠΏΡ ΡΡΠ°ΡΠΈΡ
ΡΡ, Π½ΠΎ ΠΎΠΊΠΎΠ½ΡΠ°ΡΠ΅Π»ΡΠ½ΡΠΉ ΠΏΡΠΎΡΠ΅ΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠΉ Π²ΡΠ±ΠΎΡ Π²Π½ΡΡΡΠΈ Π³ΡΡΠΏΠΏ ΡΠ°Π·Π»ΠΈΡΠ΅Π½, ΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΠ½ΠΎ, ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ΅ΡΡΡ ΠΈ Π΄ΡΡΠ³ΠΈΠΌΠΈ ΡΠ°ΠΊΡΠΎΡΠ°ΠΌΠΈ
Human Secreted Ly-6/uPAR Related Protein-1 (SLURP-1) Is a Selective Allosteric Antagonist of Ξ±7 Nicotinic Acetylcholine Receptor
SLURP-1 is a secreted toxin-like Ly-6/uPAR protein found in epithelium, sensory neurons and immune cells. Point mutations in the slurp-1 gene cause the autosomal inflammation skin disease Mal de Meleda. SLURP-1 is considered an autocrine/paracrine hormone that regulates growth and differentiation of keratinocytes and controls inflammation and malignant cell transformation. The majority of previous studies of SLURP-1 have been made using fusion constructs containing, in addition to the native protein, extra polypeptide sequences. Here we describe the activity and pharmacological profile of a recombinant analogue of human SLURP-1 (rSLURP-1) differing from the native protein only by one additional N-terminal Met residue. rSLURP-1 significantly inhibited proliferation (up to ~ 40%, EC50 ~ 4 nM) of human oral keratinocytes (Het-1A cells). Application of mecamylamine and atropine,--non-selective inhibitors of nicotinic acetylcholine receptors (nAChRs) and muscarinic acetylcholine receptors, respectively, and anti-Ξ±7-nAChRs antibodies revealed Ξ±7 type nAChRs as an rSLURP-1 target in keratinocytes. Using affinity purification from human cortical extracts, we confirmed that rSLURP-1 binds selectively to the Ξ±7-nAChRs. Exposure of Xenopus oocytes expressing Ξ±7-nAChRs to rSLURP-1 caused a significant non-competitive inhibition of the response to acetylcholine (up to ~ 70%, IC50 ~ 1 ΞΌM). It was shown that rSLURP-1 binds to Ξ±7-nAChRs overexpressed in GH4Cl cells, but does not compete with 125I-Ξ±-bungarotoxin for binding to the receptor. These findings imply an allosteric antagonist-like mode of SLURP-1 interaction with Ξ±7-nAChRs outside the classical ligand-binding site. Contrary to rSLURP-1, other inhibitors of Ξ±7-nAChRs (mecamylamine, Ξ±-bungarotoxin and Lynx1) did not suppress the proliferation of keratinocytes. Moreover, the co-application of Ξ±-bungarotoxin with rSLURP-1 did not influence antiproliferative activity of the latter. This supports the hypothesis that the antiproliferative activity of SLURP-1 is related to 'metabotropic' signaling pathway through Ξ±7-nAChR, that activates intracellular signaling cascades without opening the receptor channel
Resistance to thyroid hormone is modulated in vivo by the nuclear receptor corepressor (NCOR1)
Mutations in the ligand-binding domain of the thyroid hormone receptor Ξ² (TRΞ²) lead to resistance to thyroid hormone (RTH). These TRΞ² mutants function in a dominant-negative fashion to interfere with the transcription activity of wild-type thyroid hormone receptors (TRs), leading to dysregulation of the pituitaryβthyroid axis and resistance in peripheral tissues. The molecular mechanism by which TRΞ² mutants cause RTH has been postulated to be an inability of the mutants to properly release the nuclear corepressors (NCORs), thereby inhibiting thyroid hormone (TH)-mediated transcription activity. To test this hypothesis in vivo, we crossed ThrbPV mice (a model of RTH) expressing a human TRΞ² mutant (PV) with mice expressing a mutant Ncor1 allele (Ncor1ΞID mice) that cannot recruit a TR or a PV mutant. Remarkably, in the presence of NCOR1ΞID, the abnormally elevated thyroid-stimulating hormone and TH levels found in ThrbPV mice were modestly but significantly corrected. Furthermore, thyroid hyperplasia, weight loss, and other hallmarks of RTH were also partially reverted in mice expressing NCOR1ΞID. Taken together, these data suggest that the aberrant recruitment of NCOR1 by RTH TRΞ² mutants leads to clinical RTH in humans. The present study suggests that therapies aimed at the TRβNCOR1 interaction or its downstream actions could be tested as potential targets in treating RTH
rSLURP-1 binds Ξ±7 nAChR subunits in the human brain.
<p>Affinity purification was performed using magnetic beads covalently coupled with rSLURP-1 or non-coupled beads (Ctrl) on human temporal cortical homogenates (n = 2). Samples were submitted to gel electrophoresis and Western blotting along with samples of the homogenate used for affinity purification (Input) and the remaining homogenate after affinity purification (Output) followed by detection of nAChR subunits.</p